A Study to Investigate The Safety, Tolerability, And Immune Response of a Range of Doses of mRNA-1769 Compared With Placebo in Healthy Participants From ≥18 Years of Age to <50 Years of Age

Phase 1

Active, not recruiting

• Conditions: Smallpox; Mpox
• Interventions: Biological: mRNA-1769; Other: Placebo

• Registration Number: NCT05995275
• Lead Sponsor: ModernaTX, Inc.

Brief Summary

The goal of this study is to assess the safety, tolerability and immunogenicity of mRNA-1769 in healthy adult participants.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-08-09
• Study First Submitted QC: 2023-08-09
• Study Start: 2023-08-15
• Study First Posted: 2023-08-16
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-05
• Last Update Posted: 2024-06-07
• Primary Completion: 2025-06-13
• Study Completion: 2025-06-13

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 351

Inclusion Criteria

• Has a body mass index (BMI) between ≥18 kilogram per square meter (kg/m^2) to ≤39 kg/m^2.
• For female participants of childbearing potential: must have a negative highly sensitive pregnancy test with 28 days before the first dose of study drug, uses approved contraception during the study intervention period and for at least 3 months after the last dose of study drug, and not currently breastfeeding.

Exclusion Criteria

• History of smallpox vaccination, vaccination with any poxvirus-based vaccine, history of of/or recent exposure to Mpox (MPX) (defined as close contact with a confirmed case of MPX within the past 14 days).
• Participant should not have any significant, progressive, unstable, or uncontrolled clinical condition, including any condition that may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures per Investigator judgement.
• Participant is undergoing investigations for a potential chronic medical disorder.
• Bleeding disorder considered a contraindication to IM injection or phlebotomy.
• Dermatologic conditions that could affect local solicited AR assessments.
• History of anaphylactic reaction or allergic reactions that required medical intervention following any vaccine.
• Known or suspected allergy to any component of mRNA-1769.
• History of malignancy within previous 10 years (excluding non-melanoma skin cancer).
• Participant has any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the Investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results.
• Participant has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids, ≥10 mg/day of prednisone or equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study. Topical tacrolimus is allowed if not used within 14 days prior to the day of enrolment. Participants may be rescheduled for enrolment if they no longer meet this criterion within the Screening Period. Inhaled, nasal, and topical steroids are allowed.
• Receipt or planned receipt of: Any vaccine(s), authorised or approved by local health agency, including mRNA vaccine, ≤28 days prior to the first injection through 28 days after the last dose of investigational (IMP).
• Intravenous blood products (red cells, platelets, immunoglobulins) within 3 months prior to the first injection up to the end of the study.
• Participated in an interventional study/received an investigational product within 28 days prior to the Screening Period or plans to do so while enroled in this study.

Note: Other inclusion and exclusion criteria may apply.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
mRNA-1769 Dose B	mRNA-1769	Participants will receive IM injection of mRNA-1769 at Dose B on Day 1 and Day 29.
mRNA-1769 Dose C	mRNA-1769	Participants will receive IM injection of mRNA-1769 at Dose C on Day 1 and Day 29.
mRNA-1769 Dose A	mRNA-1769	Participants will receive intramuscular (IM) injection of mRNA-1769 at Dose A on Day 1 and Day 29.
Placebo	Placebo	Participants will receive IM injection of placebo matched to mRNA-1769 on Day 1 and Day 29.

Primary Outcome Measures

Name	Time	Method
Number of Participants with Adverse Events of Special Interest (AESIs)	Day 1 up to Day 395
Number of Participants with AEs Leading to Study and/or Treatment Discontinuation	Day 1 up to Day 395
Number of Participants with Medically-Attended AEs (MAAEs)	Day 1 up to Day 395
Number of Participants with Serious Adverse Events (SAEs)	Day 1 up to Day 395
Number of Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs) Through 7 Days After Each Investigational Medicinal Product (IMP)	Up to Day 35
Number of Unsolicited Adverse Events (AEs) Through 7 Days After Each IMP	Up to Day 57

Secondary Outcome Measures

Name	Time	Method
Geometric Mean Titer (GMT) of Neutralising Antibody (nAb) against Mpox Virus (MPXV) by Plaque reduction neutralisation test (PRNT)	Days 1 and 43
Percentage of Participants With Seroconversion Based on Neutralising Antibody Responses Against MPXV	Days 1 and 43
Percentage of Participants With Seroconversion Based on Binding Antibodies (bAb) Responses against MPXV	Days 1, 29, 43, and 57
Percentage of Participants With Seroconversion Based on Binding Antibodies Responses Against Vaccinia Virus	Days 1, 29, 43, and 57
Geometric Mean Concentration of Binding Antibodies (bAbs) Against MPXV Antigens by Meso Scale Discovery (MSD) Assay	Days 1, 29, 43, and 57
Geometric Mean Titer of Neutralising Antibody Against Vaccinia Virus (VACV) by Plaque Reduction Neutralisation Test (PRNT)	Days 1 and 43
Percentage of Participants With Seroconversion Based on Neutralising Antibody Responses Against Vaccinia Virus	Days 1 and 43
Geometric Mean Concentration of Binding Antibodies Against Vaccinia Virus Antigens by Meso Scale Discovery Assay	Days 1, 29, 43, and 57

Trial Locations

Locations (12)

Bradford Teaching Hospitals NHS Foundation Trust; 🇬🇧 Bradford, United Kingdom

Liverpool University Hospitals NHS Foundation Trust; 🇬🇧 Liverpool, United Kingdom

Barts Health NHS Trust; 🇬🇧 London, United Kingdom

University Hospitals Bristol and Weston NHS Foundation Trust; 🇬🇧 Bristol, United Kingdom

University Hospitals of Leicester; 🇬🇧 Leicester, United Kingdom

Lakeside Healthcare Research; 🇬🇧 Corby, United Kingdom

University College London Hospitals; 🇬🇧 London, United Kingdom

Medicines Evaluation Unit; 🇬🇧 Manchester, United Kingdom

North Wales Clinical Research Facility Centre; 🇬🇧 Wrexham, United Kingdom

Centre for Clinical Vaccinology and Tropical Medicine (CCVTM); 🇬🇧 Oxford, United Kingdom

Chelsea and Westminster Hospital NHS Foundation Trust; 🇬🇧 London, United Kingdom

Royal Free London NHS Foundation Trust; 🇬🇧 London, United Kingdom